Perfil de internações não eletivas em pacientes cirróticos
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Descrever o perfil clínico-epidemiológico de pacientes cirróticos com internações não eletivas na Fundação Santa Casa de Misericórdia do Pará. Métodos: Realizou-se um estudo do tipo observacional, descritivo e com delineamento transversal, a partir de análise de prontuários hospitalares eletrônicos de pacientes internados no período de abril de 2024 a setembro de 2024 em um Hospital de Referência. Resultados: Internações de 54 pacientes foram analisados, das quais a maioria apresentava diagnóstico prévio de cirrose hepática (N=38/54, 70%). A principal causa de cirrose hepática foi a alcoólica (48%), seguida pela doença hepática gordurosa não alcoólica (22%) e pela infecção crônica pelo Vírus da Hepatite C (17%). Insuficiência IHAC foi diagnosticada em 20% dos pacientes (N=11/54), com taxa de mortalidade significativamente maior quando comparados ao grupo de pacientes sem este diagnóstico (73% vs. 5%, p<0,001). Pacientes com IHAC também apresentaram maior necessidade de UTI, uso de hemocomponentes e intubação orotraqueal. Ademais, o estudo também mostrou que o escore MELD-NA não diferiu entre os pacientes que evoluíram a óbito e os que receberam alta hospitalar. Conclusão: Em conclusão, o presente estudo reafirma a gravidade da patologia e reforça a validade do uso de escores prognósticos, especialmente o CLIF-ACLF, neste perfil de pacientes.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ALLEN AM, et al. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology, 2016;64(6):2165–72.
3. BALCAR L, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure,2021;9(4):427–37.
4. CLÀRIA J, et al. The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. The Journal of Immunology, 2016;197(10):3755–61.
5. CRONST J, et al. Acute-on-Chronic Liver Failure: DiagnósticoaoTransplanteHepático. Brazilian Journal of Transplantation, 2022;25(03):e042.
6. ENGELMANN C, et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Critical Care, 2018;22(1):254.
7. FERNANDES FC, et al.Acute-on-chronic liver failure: a retrospective review of cases at a transplantation center in Brazil. Acta Cirúrgica Brasileira, 2024; 39: e392624.
8. FERNÁNDEZ J, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2017;67(10):1870–80.
9. FRANCHIS R, et al. Corrigendum to “Baveno VII – Renewing consensus in portal hypertension”. Journal of Hepatol, 2022;77(1):271–1.
10. FRIEDMAN SL. Liver fibrosis – from bench to bedside. Journal of Hepatology, 2003; 38 Suppl 1:S38–S53.
11. FURUICHI Y, NISHIGUCHI R, SATO K. Scoring system for prediction of mortality after endoscopic ligation in esophageal variceal bleeding. Digestive Endoscopy, 2024;36(10):1115-1117.
12. GUNARATHNE LS, et al. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World Journal of Gastroenterology, 2020;26(40):6111–40.
13. HSU C, et al. P59 Outcomes of patients with cirrhosis admitted to intensive care: a real-world district general hospital experience. Gut, 2024;73:A48.
14. JALAN R, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015;62(4):831–40.
15. KAMM DR, MCCOMMIS KS. Hepatic stellate cells in physiology and pathology. The Journal of Physiology, 2022;600(8):1825–37.
16. KUMAR R, et al. Acute-on-chronic liver failure. Clinical Medicine, 2020;20(5):501–4.
17. MAK LY, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nature Reviews Gastroenterology & Hepatology. 2024; 21(12): 834–851.
18. MANSOUR D, MCPHERSON S. Management of decompensated cirrhosis. Clinical Medicine, 2018;18(Suppl 2):s60–5.
19. MATTOS ÂZ, MATTOS AA. Acute-on-chronic liver failure—old concepts made clearer. Translational Gastroenterology and Hepatology,2017;2(12):111–1.
20. MORAN-SALVADOR E, MANN J. Epigenetics and Liver Fibrosis. Cellular and Molecular Gastroenterology and Hepatology, 2017;4(1):125–34.
21. MOREAU R, et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013;144(7):1426-1437.e9.
22. NADIM MK, et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016;64(3):717–35.
23. PICON RV, et al. Chronic liver failure-consortium acute-on-chronic liver failure and acute decompensation scores predict mortality in Brazilian cirrhotic patients. World Journal of Gastroenterology, 2017;23(28):5237-5245.
24. PUTIGNANO A, GUSTOT T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. Liver Transplantation, 2017;23(2):234–43.
25. RINELLA ME, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology, 2023;77(5):1797–1835.
26. SALIBA F, et al. Cirrhotic patients in the ICU. Current Opinion in Critical Care. 2013;19(2):154–60.
27. SERPER M, et al. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American journal of gastroenterology, 2023;118(2):294–303
28. SILVA PES, et al.Single-centre validation of the EASL-CLIF Consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis. Liver International, 2014;35(5):1516–23.
29. SINGAL AK, et al. ACG Clinical Guideline: Alcoholic Liver Disease. The American Journal of Gastroenterology, 2018;113(2):175–94.
30. SINGH JA, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med, 2016;14(1):137.
31. TREBICKA J, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers. Gut, 2024;73(6):1015-1024.
32. WEIL D, et al.Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis. Ann Intensive Care, 2017;7(1):33.
33. WONG RJ, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology, 2015;148(3):547–55.